lx-3

LX-3 is a selective activator of the p38 mitogen-activated protein kinase (MAPK) pathway, which de-represses a subset of endogenous genes repressed by DNA methylation.

RLX-33 是一种有效的、选择性的、能够透过血脑屏障的松弛素家族肽 3 (RXFP3) 拮抗剂，也能够阻断松弛素 3 (relaxin 3) 诱导的 ERK1 2 磷酸化。RLX-33 作用于 RXFP3、ERK1 和 ERK2 磷酸化的 IC50 分别为 2.36 μM、7.82 μM 和 13.86 μM。RLX-33 可以阻断 RXFP3 选择性激动剂 R3 I5 诱导的大鼠食物摄取增加。RLX-33 能够用于研究代谢综合征。

PLX-3618 是一款通过促进 BRD4 的多泛素化进而实现其蛋白酶体降解的单价直接降解剂，具体是通过募集 E3 连接酶底物受体 DCAF11 来执行此功能，DC50 为 12.2 nM。该化合物有效抑制多种癌细胞增殖，并在小鼠模型中显示出抗 AML (acute myeloid leukemia) 肿瘤活性，能够诱导 AML 细胞的凋亡 (apoptosis)。

Pexidartinib (PLX-3397) 是一种 CSF-1R 和 c-Kit 的抑制剂 (IC50=20 10 nM)，具有选择性、ATP 竞争性和口服活性。Pexidartinib 具有抗肿瘤活性，可以诱导细胞凋亡。

BLX3887 is an inhibitor of 15-lipoxygenase type 1 (15-LO-1; IC50 = 32 nM in a cell-free enzyme assay).1 It is selective for 15-LO-1 over 15-LO-2, which it does not inhibit, 5-LO (IC50 = 472 nM), and 12-LO (IC50 = 3,310 nM). BLX3887 inhibits the production of 15-LO metabolites selectively in eosinophils over neutrophils when used at a concentration of 10 μM. It also inhibits endocytosis in, and the migration of, isolated human peripheral blood mononuclear cell-derived dendritic cells in vitro. |1. Archambault, A.-S., Turcotte, C., Martin, C., et al. Comparison of eight 15-lipoxygenase (LO) inhibitors on the biosynthesis of 15-LO metabolites by human neutrophils and eosinophils. PLoS One 13(8), e0202424 (2018).

GLX351322 抑制 NADPH 氧化酶 4 (Nox4) 。在 NOX4 过表达的细胞中，抑制过氧化氢的产生，IC50值为 5 μM。

C18 dihydro Ceramide is a bioactive sphingolipid and precursor in the de novo synthesis of C18 ceramide that lacks the 4,5-trans double bond. [1] Increased C18 dihydroceramide lipid levels lead to increased triacylglycerol storage and autophagosome accumulation as well as upregulation of the fibrosis markers α-SMA and FGF2 in Chang and LX-2 liver cells. C18 dihydro Ceramide is elevated in the plasma of pre-diabetics up to 9 years prior to the onset of type 2 diabetes. [2] It is also elevated in the skin of patients with lesional atopic dermatitis.[3]

Dual Galectin-3 EGFR-IN-1 (Compound 29) 是一种双重抑制剂，其对Galectin-3和EGFR的KD分别为52.29 μM和3.31 μM。它能够抑制TGF-β诱导的肝星状细胞 (HSC) 的活化，诱导LX-2细胞凋亡 (apoptosis)，并具有抗肝纤维化的活性。

LX-039 是一种高效的、选择性的、口服具有活力的雌激素受体降解剂 (EC50: 2.99 nM)，具有抗肿瘤作用。LX-039 有吲哚 C-3 氯原子。LX-039 具有良好的小鼠药代动力学性质、低清除、高血药浓度和口服暴露率。

LX2343 是一种非 ATP 竞争性 PI3K 抑制剂，IC50 为 15.99±3.23 μM。它是一种 BACE1 酶抑制剂，IC50 值为 11.43±0.36 μM。它在促进 Aβ 清除中刺激自噬。